Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Udo Bonnet, Ann-Kristin Kanti, Norbert Scherbaum & Michael Specka. (2023) The Role of Gabapentinoids in the Substance Use Pattern of Adult Germans Seeking Inpatient Detoxification Treatment – A Pilot Study. Journal of Psychoactive Drugs 55:1, pages 102-111.
Read now
Read now
Alessandra Morano, Caterina Palleria, Rita Citraro, Valentina Nesci, Carmen De Caro, Anna Teresa Giallonardo, Giovambattista De Sarro, Emilio Russo & Carlo Di Bonaventura. (2019) Immediate and controlled-release pregabalin for the treatment of epilepsy. Expert Review of Neurotherapeutics 19:12, pages 1167-1177.
Read now
Read now
Paweł Kawalec, Agnieszka Cierniak, Andrzej Pilc & Gabriel Nowak. (2015) Pregabalin for the treatment of social anxiety disorder. Expert Opinion on Investigational Drugs 24:4, pages 585-594.
Read now
Read now
Maximilian Gahr, Roland W. Freudenmann, Markus A. Kölle & Carlos Schönfeldt-Lecuona. (2014) Pregabalin and addiction: lessons from published cases. Journal of Substance Use 19:6, pages 448-449.
Read now
Read now
Charlotte Both, Georg Kojda & Christian Lange-Asschenfeldt. (2014) Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin. Expert Review of Neurotherapeutics 14:1, pages 29-38.
Read now
Read now
Kinga Sałat, Tadeusz Librowski, Barbara Nawiesniak & Monika Gluch-Lutwin. (2013) Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain. Neurological Research 35:9, pages 948-958.
Read now
Read now
Articles from other publishers (22)
Michael Soyka. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
494
509
.
Ying‐Chih Cheng, Yu‐Chen Huang & Wei‐Lieh Huang. (2020) Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta‐analysis. Human Psychopharmacology: Clinical and Experimental 35:6, pages 1-11.
Crossref
Crossref
Arash Mowla & Mehrnoosh Ghaedsharaf. (2019) Pregabalin augmentation for resistant obsessive–compulsive disorder: a double-blind placebo-controlled clinical trial. CNS Spectrums 25:4, pages 552-556.
Crossref
Crossref
E. M. Krupitsky, K. V. Rybakova, E. P. Skurat, N. V. Semenova & N. G. Neznanov. (2020) A double blind placebo controlled randomized clinical trial of the efficacy and safety of pregabalin in induction of remission in patients with alcohol dependence. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:1, pages 33.
Crossref
Crossref
. 2019. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
119
.
Sharon Rees. (2018) Gabapentin and pregabalin in the pain setting: All you need to know. Nurse Prescribing 16:7, pages 332-340.
Crossref
Crossref
Subhajit Chakravorty, Ryan G. Vandrey, Sean He & Michael D. Stein. (2018) Sleep Management Among Patients with Substance Use Disorders. Medical Clinics of North America 102:4, pages 733-743.
Crossref
Crossref
. 2017. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
111
.
Rainer Freynhagen, Miroslav Backonja, Stephan Schug, Gavin Lyndon, Bruce Parsons, Stephen Watt & Regina Behar. (2016) Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review. CNS Drugs 30:12, pages 1191-1200.
Crossref
Crossref
Stefania Chiappini & Fabrizio Schifano. (2016) A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database. CNS Drugs 30:7, pages 647-654.
Crossref
Crossref
Alexandra Röllin. (2016) Benzodiazepin-Abhängigkeit. pharma-kritik 37:online.
Crossref
Crossref
Giovanni Martinotti, Georgios Papazisis, Rita Santacroce, Dimitrios Kouvelas, Eduardo Cinosi, Matteo Lupi & Massimo di Giannantonio. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
945
951
.
Vincenzo Arcoraci & Edoardo Spina. 2016. Pharmacovigilance in Psychiatry. Pharmacovigilance in Psychiatry
191
207
.
Katrin Janhsen, Patrik Roser & Knut Hoffmann. (2015) The Problems of Long-Term Treatment With Benzodiazepines and Related Substances. Deutsches Ärzteblatt international.
Crossref
Crossref
Rainer Freynhagen, Michael Serpell, Birol Emir, Ed Whalen, Bruce Parsons, Andrew Clair & Mark Latymer. (2013) A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain. Pain Practice 15:1, pages 47-57.
Crossref
Crossref
. 2015. Therapie Psychischer Erkrankungen. Therapie Psychischer Erkrankungen
e1
e96
.
Parisa Hasanein & Saeed Shakeri. (2014) Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. European Journal of Pharmacology 742, pages 113-117.
Crossref
Crossref
Marco Di Nicola, Luisa De Risio, Mauro Pettorruso, Giulio Caselli, Franco De Crescenzo, Kevin Swierkosz-Lenart, Giovanni Martinotti, Giovanni Camardese, Massimo Di Giannantonio & Luigi Janiri. (2014) Bipolar disorder and gambling disorder comorbidity: Current evidence and implications for pharmacological treatment. Journal of Affective Disorders 167, pages 285-298.
Crossref
Crossref
Pirkko Kriikku, Lars Wilhelm, Janne Rintatalo, Jukka Hurme, Jan Kramer & Ilkka Ojanperä. (2014) Pregabalin serum levels in apprehended drivers. Forensic Science International 243, pages 112-116.
Crossref
Crossref
Panagiotis Oulis, Stamatina Kalogerakou, Eleni Anyfandi, George Konstantakopoulos, Vassiliki-Maria Papakosta, Vasilios Masdrakis & Eleftheria Tsaltas. (2014) Cognitive effects of pregabalin in the treatment of long-term benzodiazepine-use and dependence. Human Psychopharmacology: Clinical and Experimental 29:3, pages 224-229.
Crossref
Crossref
. 2014. Therapie Psychischer Erkrankungen. Therapie Psychischer Erkrankungen
1
91
.
Maximilian Gahr, Roland. W. Freudenmann, Christoph Hiemke, Makus A. Kölle & Carlos Schönfeldt-Lecuona. (2013) Pregabalin abuse and dependence in Germany: results from a database query. European Journal of Clinical Pharmacology 69:6, pages 1335-1342.
Crossref
Crossref